Literature DB >> 20146218

Non-cerebellar primitive neuroectodermal tumors (PNET): summary of the Milan consensus and state of the art workshop on marrow ablative chemotherapy with hematopoietic cell rescue for malignant brain tumors of childhood and adolescents.

Jason Fangusaro1, Maura Massimino, Stefan Rutkowski, Sridharan Gururangan.   

Abstract

CNS non-cerebellar primitive neuroectodermal tumors (PNET) represent <5% of all childhood brain tumors. Despite similar therapies, these patients have had significantly worse outcomes compared to patients with medulloblastoma. Although these tumors have historically been considered analogous to medulloblastoma, there is growing evidence that they are biologically distinct. Since these tumors are relatively rare, there are few large series in the literature. Here we present the international experience treating these patients with a variety of therapies, including marrow ablative chemotherapy followed by autologous hematopoietic cell rescue.

Entities:  

Mesh:

Year:  2010        PMID: 20146218     DOI: 10.1002/pbc.22373

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  7 in total

1.  DNA copy number alterations in central primitive neuroectodermal tumors and tumors of the pineal region: an international individual patient data meta-analysis.

Authors:  André O von Bueren; Joachim Gerss; Christian Hagel; Haoyang Cai; Marc Remke; Martin Hasselblatt; Burt G Feuerstein; Sarah Pernet; Olivier Delattre; Andrey Korshunov; Stefan Rutkowski; Stefan M Pfister; Michael Baudis
Journal:  J Neurooncol       Date:  2012-07-07       Impact factor: 4.130

2.  New gene signatures for pediatric brain tumors: a step forward in the understanding of molecular basis of CNS PNET.

Authors:  Raúl Alelú-Paz; Santiago Ropero
Journal:  Transl Pediatr       Date:  2013-01

3.  High-dose chemotherapy with autologous hematopoietic stem-cell rescue for pediatric brain tumor patients: a single institution experience from UCLA.

Authors:  Eduard H Panosyan; Alan K Ikeda; Vivian Y Chang; Dan R Laks; Charles L Reeb; La Vette Bowles; Joseph L Lasky; Theodore B Moore
Journal:  J Transplant       Date:  2011-04-14

4.  Long-term safety of growth hormone replacement therapy after childhood medulloblastoma and PNET: it is time to set aside old concerns.

Authors:  Alice Indini; Elisabetta Schiavello; Veronica Biassoni; Luca Bergamaschi; Maria Chiara Magni; Nadia Puma; Stefano Chiaravalli; Federica Pallotti; Ettore Seregni; Barbara Diletto; Emilia Pecori; Lorenza Gandola; Geraldina Poggi; Maura Massimino
Journal:  J Neurooncol       Date:  2016-10-21       Impact factor: 4.130

5.  Treatment of young children with CNS-primitive neuroectodermal tumors/pineoblastomas in the prospective multicenter trial HIT 2000 using different chemotherapy regimens and radiotherapy.

Authors:  Carsten Friedrich; André O von Bueren; Katja von Hoff; Nicolas U Gerber; Holger Ottensmeier; Frank Deinlein; Martin Benesch; Robert Kwiecien; Torsten Pietsch; Monika Warmuth-Metz; Andreas Faldum; Joachim Kuehl; Rolf D Kortmann; Stefan Rutkowski
Journal:  Neuro Oncol       Date:  2012-12-07       Impact factor: 12.300

6.  Proteomic analysis of cerebrospinal fluid from children with central nervous system tumors identifies candidate proteins relating to tumor metastatic spread.

Authors:  Filippo Spreafico; Italia Bongarzone; Sara Pizzamiglio; Ruben Magni; Elena Taverna; Maida De Bortoli; Chiara M Ciniselli; Elena Barzanò; Veronica Biassoni; Alessandra Luchini; Lance A Liotta; Weidong Zhou; Michele Signore; Paolo Verderio; Maura Massimino
Journal:  Oncotarget       Date:  2017-07-11

7.  Institutional experience of paediatric high-grade central nervous system tumours: an analysis of 74 patients and review of the literature.

Authors:  Faruk Guclu Pinarli; Aynur Oguz; Ceyda Karadeniz; Arzu Okur; Avni Sarac; Kemali Baykaner; Huseyin Bora; Aylar Poyraz
Journal:  Contemp Oncol (Pozn)       Date:  2012-02-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.